AnGes : Tie2 receptor agonist (AV 001), co development product, received fast track designation from the U.S. FDA

May 29, 2024


Company Name: AnGes Inc.


Presentative: Ei Yamada, President & CEO


Tie2 receptor agonist ,co-development...

Related Keywords

United States ,Canada ,Toronto ,Ontario ,Japan ,Brian Jahns ,Drug Administration ,Anges Inc ,Company Name ,Sunnybrook Research Institute At Hospital ,Vasomune Therapeutics Inc ,Vasomune Inc ,National Research Council Canada ,Vasomune Therapeutics ,Fast Track ,Therapeutics Inc ,Track Designation ,Chief Operating ,United States Department ,Sunnybrook Research Institute ,Sunnybrook Hospital ,Hepatocyte Growth Factor ,